A Message From Our Leader
The LPIRP is enabling medical advances consistent with the belief that healthcare in the future needs to be more personalized. To make healthcare more personalized, LPIRL will create efficient evidence-generation strategies and ways of adopting new technologies.
About our Program
Advances in the biomedical sciences can take as long as 17 years to reach clinical acceptance and cost billions of dollars to create in the process.
The Longevity, Prevention and Interception Research Lab (LPIRL) focuses on the identification and characterization of factors influencing longevity and the ability to prevent disease and catch disease manifestations early. This includes developing and testing interventions meant to sustain health and prevent disease. The LPIRL develops analytical methods, evidence synthesis strategies, and clinical trial designs to enable efficient discovery, characterization, and translation of findings with clinical and public health utility.
- The LPIRP pursues integrated and translational research, from basic discoveries to clinical trials.
- The LPIRP has published over 625 peer-reviewed papers, over 350 invited presentations, generated 13 patents or patent applications, and has had over 75 graduate students and postdoctoral trainees pass through it.
- The LPIRP is the home for the oversight of the large and scientifically diverse NIA-funded Longevity Consortium.
- The LPIRP has a diverse source of collaborations and funding, including connections to the LPI clinic run by Dr. Laura Goetz, a world-leader in advancing clinical care through patient engagement and state-of-the-field technologies.
Clinical and health intervention learning systems.
Broad levels at which precision health research is pursued and their potential contribution to, and benefit from, focused Single Case Experimental Design based trials of individual patients. Each of the 4 columns in the upper part reflects a focus area in the literature seeking to identify factors, protocols, and/or strategies for treating individual patients differently based on their unique genetic, physiologic, exposure and behavioral profiles. The feedback between focused patient-oriented SCED studies and the use of population-based predictions can contribute to a true ‘Health Learning System’. Nature Communications | (2025)16:5024.
Schork Lab Facts and Figures
The LPIRP is highly collaborative (4 large, funded grants; many collaborative projects).
The LPIRP believes in nurturing relationships with commercial groups to advance innovations in healthcare and has active engagements with 10 different companies.
The LPIRP interacts with non-profit, government and regulatory agencies; e.g., 20 institutions via the Longevity Consortium.
Schork Lab Clinical Trials
The LPIRP is building a learning system where prediction models of disease risk or intervention response, e.g., based on Artificial Intelligence (AI), are used to support clinical decisions. The reliability of those predictions is vetted via focused, built-for-purpose trials whose results can be fed back to the system for updating and error correction.